Encouraged by a modestly-improving public market for biotechs, gene editing startup CRISPR Therapeutics disclosed plans late Friday to raise up to $90 million in an IPO. But the question remains whether CRISPR can do much better on the stock market than the other two publicly-traded gene editing companies, both of which are based in Cambridge and held IPOs earlier this year.
CRISPR Therapeutics is based in Switzerland but has its largest lab and office space by far in Cambridge, inhabiting one of…
Encouraged by a modestly-improving public market for biotechs, gene editing startup CRISPR Therapeutics disclosed plans late Friday to raise up to $90 million in an IPO. But the question remains whether CRISPR can do much better on the stock market than the other two publicly-traded gene editing companies, both of which are based in Cambridge and held IPOs earlier this year.
CRISPR Therapeutics is based in Switzerland but has its largest lab and office space by far in Cambridge, inhabiting one of…